Mode of action and mechanisms of resistance for antimalarial drugs

Pharmacology and Therapeutics

Volumn 89, Issue 2, 2001, Pages 207-219

  Olliaro, P ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Antimalarial drugs; Malaria; Mechanisms of resistance; Mode of action

Indexed keywords

ANTIMALARIAL AGENT; ARTEETHER; ARTEMETHER; ARTESUNATE; ATOVAQUONE; CYCLOGUANIL; DIHYDROARTEMISININ; DIHYDROFOLATE REDUCTASE; DIHYDROOROTATE DEHYDROGENASE; DIHYDROPTEROATE SYNTHASE; FOLIC ACID ANTAGONIST; PROGUANIL; PYRIMETHAMINE; QUINOLINE DERIVATIVE; SULFONAMIDE; SULFONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; BACTERIAL CHROMOSOME; CELL VACUOLE; DRUG ACCUMULATION; DRUG MECHANISM; DRUG TARGETING; DRUG TRANSPORT; GENE MUTATION; HUMAN; MALARIA; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMALARIALS; ARTEMISININS; ATOVAQUONE; CHLOROGUANIDE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FOLIC ACID ANTAGONISTS; HUMANS; LACTONES; MUTATION; NAPHTHOQUINONES; NUCLEIC ACIDS; PLASMODIUM; QUINOLINES; SESQUITERPENES;

EID: 0035060361     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(00)00115-7     Document Type: Review

References (113)

1. The chemical mechanism of β-hematin formation studied by Mössbauer spectroscopy
2. Heme degradation in the presence of glutathione. A proposed mechanism to account for the high levels of non-heme iron found in the membranes of hemoglobinopathic red blood cells
3. Non-iron porphyrins inhibit beta-haematin (malaria pigment) polymerisation
4. A microtiter-based method for measuring the heme-polymerization inhibitory activity (HPIA) of antimalarial drugs
5. The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin
6. Mechanisms of multidrug transporters
7. A comparison of the phenomenology and genetics of multidrug resistance in cancer cells and quinoline resistance in Plasmodium falciparum
8. Rapid chloroquine efflux phenotype in both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum
9. Access to hematin: The basis of chloroquine resistance
10. Chloroquine uptake and activity is determined by binding to ferriprotoporphyrin IX in Plasmodium falciparum
11. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine
12. Inhibition of DNA and RNA polymerase reactions by chloroquine
13. A P-glycoprotein homologue of Plasmodium falciparum is located on the digestive vacuole
14. Antimalarial activity of artemisinin (Qinghaosu) and related trioxanes: Mechanism(s) of action
15. In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment
16. Malarial haemozoin/beta-haematin supports haem polymerization in the absence of protein
17. Digestive vacuolar pH of intact intraerythrocytic P. falciparum either sensitive or resistant to chloroquine
18. Quinoline anti-malarial drugs inhibit spontaneous formation of beta-haematin (malaria pigment)
19. Characterisation of synthetic beta-haematin and effects of the antimalarial drugs quinidine, halofantrine, desbutylhalofantrine and mefloquine on its formation
20. Structure-function relationships in aminoquinolines: Effect of amino and chloro groups on quinoline-hematin complex formation, inhibition of beta-hematin formation, and antiplasmodial activity
21. Allelic modifications of the cg2 and cg1 genes do not alter the chloroquine response of drug-resistant Plasmodium falciparum
22. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance
23. Quinoline antimalarials: Mechanisms of action and resistance
24. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80)
25. Biochemistry of Plasmodium on the web
26. Current concepts and new ideas on the mechanism of action of quinoline-containing antimalarials
27. Kinetic modelling of chloroquine uptake by malaria-infected erythrocytes. Assessment of the factors that may determine drug resistance
28. Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action
29. An integrated model of chloroquine action
30. Inoculum effect with chloroquine and Plasmodium falciparum
31. Hemoglobin degradation in the malaria parasite Plasmodium falciparum: An ordered process in a unique organelle
32. Biochemistry of multidrug resistance mediated by the multidrug transporter
33. Formation of hydroxylicosatetraenoic acids from haemozoin-catalised oxidation of arachidonic acid
34. Ring opening of artemisinin (qinghaosu) and dihydroartemisinin and interception of the open hydroperoxides with formation of N-oxides - A chemical model for antimalarial mode of action
35. The multiple dose pharmacokinetics of proguanil
36. Lapinone, menoctone, hydroxyquinolinequinones and similar structures
37. Atovoquone - A novel broad-spectrum anti-infective drug
38. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport
39. The mechanism of antimalarial action of artemisinin (Qinghaosu)
40. Antimalarials increase vesicle pH in Plasmodium falciparum
41. Purification, characterization and localization of mitochondrial dihydroorotate dehydrogenase in Plasmodium falciparum, human malaria parasite
42. The antimalarial action on Plasmodium falciparum of qinghaosu and artesunate in combination with agents which modulate oxidant stress
43. Molecular assays for surveillance of antifolate-resistant malaria
44. Thymidylate synthase - Dihydrofolate reductase in protozoa
45. High prevalence of mutations in the dihydrofolate reductase gene of Plasmodium falciparum in isolates from Tanzania without evidence of an association to clinical sulfadoxine/pyrimethamine resistance
46. Multidrug resistance mediated by multidrug resistance protein (MRP) gene
47. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand
48. Malarone (atovaquone and proguanil hydrochloride): A review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group
49. Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials
50. Is one gene the key to chloroquine-resistant malaria?
51. Chloroquine as an intercalator: A hypothesis revived
52. Artemisinin antimalarials: Mechanisms of action and resistance
53. Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu)
54. Artemisinin and the antimalarial endoperoxides: From herbal remedy to targeted chemotherapy
55. Central role of haemoglobin degradation in the mechanism of action of the 4-aminoquinolines, the quinoline methanols and the phenantrene methanols
56. Cytochrome P-450 activity in malaria parasites and its possible relationship to chloroquine resistance
57. Enhancement of drug susceptibility in Plasmodium falciparum in vitro Plasmodium berghei in vivo by mixed-function oxidase inhibitors
58. Kenyan Plasmodium falciparum field isolates: Correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain
59. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: Genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites
60. Possible modes of action of the artemisinin-type compounds
61. An overview of chemotherapeutic targets for antimalarial drug discovery
62. Malaria: The submerged disease
63. 4-Aminoquinolines - Past, present and future: A chemical perspective
64. Hemozoin production by Plasmodium falciparum: Variation with strain and exposure to chloroquine
65. The structure of malaria pigment beta-haematin
66. Correlation of antimalarial activity of artemisinin derivatives with binding affinity with ferroprotoporphyrin IX
67. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malaria parasites
68. A strong association between mefloquine and halofantrine resistance and amplification, overexpression, and mutation in the P-glycoprotein gene homolog (pfmdr) of Plasmodium falciparum in vitro
69. The chemotherapy of rodent malaria. LVI. Studies on the development of resistance to natural and synthetic endoperoxides
70. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance
71. P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: Epidemiology and role of clinical resistance to antifolates
72. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand
73. Variations in frequencies of drug resistance in Plasmodium falciparum
74. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells
75. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum
76. Amplification of P-glycoprotein genes in multidrug resistant mammalian cell lines
77. Is alkylation the main mechanism of action of the antimalarial drug artemisinin?
78. Analysis of the steady-state and initial rate of doxorubicin efflux from a series of multidrug resistant cells expressing different levels of P-glycoprotein
79. Identification of a chloroquine importer in Plasmodium falciparum: Differences in import kinetics are generally linked with the chloroquine-resistant phenotype
80. Selection and synergy in plasmodium falciparum
81. Plasmodium falciparum: Asparagine mutant at residue 108 of dihydrofolate reductase is an optimal antifolate-resistant single mutant
82. Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites
83. An iron-carboxylate bond links the heme units of malaria pigment
84. A mechanism for the synergistic antimalarial action of atovaquone and proguanil
85. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite
86. Complex polymorphisms in an approximately kDa protein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa
87. On the molecular mechanism of chloroquine's antimalarial action
88. Chloroquine inhibits heme-dependent protein synthesis in Plasmodium falciparum
89. Mutations in the cytochrome b gene of Plasmodium berghei conferring resistance to atovaquone
90. Drugs used in the chemotherapy of protozoal infections
91. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum
92. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum
93. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria
94. Mitochondrial physiology as a target for atovaquone and other antimalarials
95. Structural features of Plasmodium cytochrome b that may underlie susceptibility to 8-aminoquinolines and hydroxynaphthoquinones
96. Characterization of a hemoglobin-degrading, low molecular weight protease from Plasmodium falciparum
97. Structural specificity of chloroquine-hematin binding related to inhibition of hematin polymerization and parasite growth
98. Stage-specific transcripts of Plasmodium falciparum pfmdr1 gene
99. Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure
100. Resistance to antifolates in Plasmodium falciparum, monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins
101. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization
102. A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparum suitable for investigating Fansidar resistance
103. Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy
104. Antimalarial interaction with ferriprotoporphyrin IX monomer and its relationship to activity of blood schizonticides
105. Antimalarial drug discovery: Development of inhibitors of dihydrofolate reductase active in drug resistance
106. The efficacy of antifolate antimalarial combinations in Africa: A predictive model based on pharmacodynamic and pharmacokinetic analyses
107. More on the efficacy of antifolate antimalarial combinations in Africa
108. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
109. Why is it that antimalarial drug treatments do not always work?
110. Amplification of pfmdr1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum in Thailand
111. Susceptibility of human malaria parasites to chloroquine is pH dependent
112. The fate of ferriprotorphyrin IX in malaria infected erythrocytes in conjunction with the mode of action of antimalarial drugs